The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Yun, Cai-Hong, Mengwasser, Kristen E., Toms, Angela V., Woo, Michele S., Greulich, Heidi, Wong, Kwok-Kin, Meyerson, Matthew, Eck, Michael J.·2008·Proceedings of the National Academy of Sciences
DOI 10.1073/pnas.0709662105

Cited by (1,002)

Items 901–1,000 of 1,002

  1. Biophysical characterization of drug‐resistant mutants of fibroblast growth factor receptor 1
    Kaito Yoza, Rika Himeno, Shinjiro Amano · 2016 · Genes to Cells
  2. Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective
    Shui-Ming Bao, Qinghui Hu, Wen-Ting Yang, Yao Wang, Yin-Ping Tong, Wen-Dai Bao · 2019 · Anti-Cancer Agents in Medicinal Chemistry
  3. Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells
    Ying Lin, Kazuma Higashisaka, Takuya Shintani et al. · 2020 · Scientific Reports
  4. Phenethyl isothiocyanate synergistically induces apoptosis with Gefitinib in non–small cell lung cancer cells via endoplasmic reticulum stress‐mediated degradation of Mcl‐1
    Qicheng Zhang, Mengmeng Chen, Limin Cao, Yinghui Ren, Xueru Guo, Xiang Wu, Ke Xu · 2020 · Molecular Carcinogenesis
  5. A Review of Epidermal Growth Factor Receptor/HER2 Inhibitors in the Treatment of Patients With Non–Small-Cell Lung Cancer
    Ramaswamy Govindan · 2010 · Clinical Lung Cancer
  6. Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
    Rossana Berardi, Matteo Santoni, Francesca Morgese, Ballatore, Savini, Onofri, Mazzanti, Mirco Pistelli, Riccardo Pierantoni, De Lisa et al. · 2013 · OncoTargets and Therapy
  7. Lazertinib: breaking the mold of third-generation EGFR inhibitors
    Kishan B. Patel, David E. Heppner · 2025 · RSC Medicinal Chemistry
  8. ALK and NSCLC: Targeted therapy with ALK inhibitors
    Bengt Hallberg, Ruth Helen Palmer · 2011 · F1000 Medicine Reports
  9. Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants
    Byung Min Chung · 2014 · World Journal of Clinical Oncology
  10. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
    Dario Presutti, Simonetta Santini, Beatrice Cardinali, Giuliana Papoff, Cristiana Lalli, Simone Samperna, Valentina Fustaino, Giuseppe Giannini, Giovina Ruberti · 2015 · PLoS ONE
  11. Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
    Lijun Dong, Dan Lei, Haijun Zhang · 2017 · Oncotarget
  12. Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non–Small Cell Lung Cancer: A Single-Center Experience
    Nadza Tokaca, Sarah E. Barth, Mary E.R. O'Brien, Jaishree Bhosle, Nicos Fotiadis, Andrew Charles Wotherspoon, LISA A. THOMPSON, Sanjay Popat · 2017 · Journal of Thoracic Oncology
  13. miR-135a Confers Resistance to Gefitinib in Non-Small Cell Lung Cancer Cells by Upregulation of RAC1
    Tingting Zhang, Ning Wang · 2018 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · Retracted
  14. IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer
    Shang‐Gin Wu, Tzu‐Hua Chang, Meng‐Feng Tsai, Yinan Liu, Chia‐Lang Hsu, Yih‐Leong Chang, Chong‐Jen Yu, Jin‐Yuan Shih · 2019 · Cancers
  15. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC
    Shuo Yang, Shiqi Mao, Xuefei Li, Chao Zhao, Qian Liu, Xiaofei Yu, Yan Wang, Yiwei Liu, Yingying Pan, Chunyan Wang et al. · 2019 · Lung Cancer
  16. Landscape of drug-resistance mutations in kinase regulatory hotspots
    Pora Kim, Hanyang Li, Junmei Wang, Zhongming Zhao · 2020 · Briefings in Bioinformatics
  17. Molecular mechanism and pharmacokinetics of flavonoids in the treatment of resistant EGF receptor‐mutated non‐small‐cell lung cancer: A narrative review
    Xuewen Wang, Bing Chen, Dafen Xu, Zhijun Li, Hao Liu, Zhengjun Huang, Kangping Huang, Xinhua Lin, Hong Yao · 2021 · British Journal of Pharmacology
  18. Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC
    Thomas W. Gero, David E. Heppner, Tyler S. Beyett et al. · 2022 · Bioorganic & Medicinal Chemistry Letters
  19. Genetic alterations shaping tumor response to anti-EGFR therapies
    Javier Vaquero, Allan Pavy, Ester Gonzalez‐Sanchez, Mark Meredith, Ander Arbelaiz, Laura Fouassier · 2022 · Drug Resistance Updates
  20. DoubleSG-DTA: Deep Learning for Drug Discovery: Case Study on the Non-Small Cell Lung Cancer with EGFRT790M Mutation
    Yongtao Qian, Wanxing Ni, Xingxing Xianyu, Liang Tao, Qin Wang · 2023 · Pharmaceutics
  21. Development of a Novel, Fully-Automated Genotyping System: Principle and Applications
    Shun-ichi Suzuki, Mariko Komori, Mitsuharu Hirai, Norio Ureshino, Shinya H Kimura · 2012 · Sensors
  22. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer
    Qiong Zhao · 2012 · Oncology Reports
  23. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
    Mariacarmela Santarpía, Giuseppe Altavilla, Maria Salazar, Ignacio Magrí, Giuseppe Pettineo, Sara Benecchi, Rafael Rosell · 2011 · Expert Review of Respiratory Medicine
  24. Screening of epidermal growth factor receptor inhibitors in natural products by capillary electrophoresis combined with high performance liquid chromatography–tandem mass spectrometry
    Feng Li, Yanmei Zhang, Danye Qiu, Jingwu Kang · 2015 · Journal of Chromatography A
  25. What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small Molecule
    Jordi Ahnert Rodon, Nathanael S. Gray, Tony S.K. Mok, Justin F. Gainor · 2019 · American Society of Clinical Oncology Educational Book
  26. Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
    Laura Pacini, Andrew D. Jenks, Simon Vyse, Christopher P. Wilding, Amani Arthur, Paul H. Huang · 2021 · Pharmacogenomics and Personalized Medicine
  27. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases
    Yan Zhu, Xiche Hu · 2022 · Molecules
  28. Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
    Yuji Sano, Eri Hashimoto, Noriaki Nakatani, Masaichi Abe, Yasuko Satoh, Kiyoaki Sakata, Toshihiko Fujii, Kaori Fujimoto-Ouchi, Masamichi Sugimoto, Shigehisa Nagahashi et al. · 2014 · Molecular Cancer Therapeutics
  29. Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
    Paola Ulivi · 2016 · International Journal of Molecular Sciences
  30. Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases
    Janina Niggenaber, Julia Hardick, Jonas Lategahn, Daniel Rauh · 2019 · Journal of Medicinal Chemistry
  31. Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial
    Jaafar Bennouna, Nicolas Girard, Clarisse Audigier-Valette, Aurélie Le Thuaut, R. Gervais, Philippe Masson, M. Marcq, Olivier Molinier, Alexis Benjamin Cortot, Didier Debieuvre et al. · 2019 · Clinical Lung Cancer
  32. Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance
    Hai‐Kui Yang, Ruohong Yan, Ying Jiang, Zichao Yang, Xingmei Zhang, Mingfeng Zhou, Xiaoyun Wu, Tingting Zhang, Jiajie Zhang · 2019 · European Journal of Medicinal Chemistry
  33. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer
    Kyoungmin Lee, Deokhoon Kim, Shinkyo Yoon, Ki Hyeong Lee, Sang‐We Kim · 2021 · European Journal of Cancer
  34. Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation
    Yuhong Jiang, Xin Zhuo, Xiujuan Fu · 2021 · Frontiers in Pharmacology
  35. Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers
    Lu Liu, Wěi Li, Le Yang, Zitao Guo, Hao Xue, Ningjie Xie, Xiaoyan Chen · 2021 · Acta Pharmacologica Sinica
  36. Combined Treatment withEpimedium koreanumNakai Extract and Gefitinib Overcomes Drug Resistance Caused by T790M Mutation in Non-Small Cell Lung Cancer Cells
    Jie Song, Rongling Zhong, Houcai Huang, Zhenhai Zhang, Dongmei Ding, Hongmei Yan, E Sun, Xiao‐Bin Jia · 2014 · Nutrition and Cancer
  37. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer
    Xinghao Ai, Shengping Shen, Lan Shen · 2015 · Biochimie
  38. Afatinib for the treatment of advanced non-small-cell lung cancer
    Carlo Genova, Erika Rijavec, Giulia Barletta, Giovanni Burrafato, Federica Biello, Maria Giovanna Dal Bello, Simona Coco, Anna Truini, Angela Alama, Francesco Boccardo et al. · 2014 · Expert Opinion on Pharmacotherapy
  39. Characterization of the Ligand Receptor Encounter Complex and Its Potential for in Silico Kinetics-Based Drug Development
    Karim M. ElSawy, Reidun Twarock, David Philip Lane, Chandra Shekhar Verma, Leo S. D. Caves · 2011 · Journal of Chemical Theory and Computation
  40. Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective
    Michael Cabanero, Randeep S. Sangha, Brandon S. Sheffield, Mahadeo A. Sukhai, Mini Pakkal, Suzanne Kamel‐Reid, Aly Karsan, Diana N. Ionescu, Rosalyn Anne Juergens, Charles Andrew Butts et al. · 2017 · Current Oncology
  41. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2
    Martiniano Bello, Lucia Saldaña-Rivera, José Correa‐Basurto, Juan Benjamín García-Vázquez, Víctor Armando Sánchez-Espinosa · 2018 · International Journal of Biological Macromolecules
  42. Effect of double mutations T790M/L858R on conformation and drug-resistant mechanism of epidermal growth factor receptor explored by molecular dynamics simulations
    Fangfang Yan, Xinguo Liu, Shaolong Zhang, Jing Su, Qinggang Zhang, Jianzhong Chen · 2018 · RSC Advances
  43. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFRT790M mutant cell lines
    Lei Zhao, Tingting Fan, Zhichao Shi, Chao Ding, Cunlong Zhang, Zigao Yuan, Qinsheng Sun, Chunyan Tan, Bizhu Chu, Yuyang Jiang · 2021 · European Journal of Medicinal Chemistry
  44. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation
    Bin Zhang, Zichen Xu, Qingqing Liu, Shengjin Xia, Zhikun Liu, Zhi‐Xin Liao, Shaohua Gou · 2021 · Bioorganic Chemistry
  45. Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives
    Ahmed Elkamhawy, Seohyun Son, Hwa Young Lee et al. · 2022 · Pharmaceuticals
  46. Deciphering the Shared and Specific Drug Resistance Mechanisms of Anaplastic Lymphoma Kinase via Binding Free Energy Computation
    Yang Yu, Zhe Wang, Lingling Wang · 2023 · Research
  47. HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer
    Shuyan Han, Zhihua Tian, Huifang Tian et al. · 2023 · Cell Death Discovery
  48. Irreversible EGFR-TKIs: dreaming perfection.
    Lorenza Maria Landi, Federico Cappuzzo · 2013 · Europe PMC (PubMed Central)
  49. Emerging treatment for advanced lung cancer withEGFRmutation
    Cengiz Inal, Emrullah Yilmaz, Bilal Piperdi, Roman Perez-Soler, Haiying Cheng · 2015 · Expert Opinion on Emerging Drugs
  50. Finding chemical drugs for genetic diseases
    Huiyong Sun, Tingjun Hou, Hongyu Zhang · 2014 · Drug Discovery Today
  51. A Water-Based Mechanism of Specificity and Resistance for Lapatinib with ErbB Family Kinases
    Yulin Huang, Robert C. Rizzo · 2012 · Biochemistry
  52. Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
    Noemı́ Reguart · 2010 · Cancer Management and Research
  53. Discovery of 7-azaindole based anaplastic lymphoma kinase (ALK) inhibitors: Wild type and mutant (L1196M) active compounds with unique binding mode
    Venkateshwar Rao Gummadi, Sujatha Rajagopalan, Chung Yeng Looi et al. · 2013 · Bioorganic & Medicinal Chemistry Letters
  54. The challenge of developing robust drugs to overcome resistance
    Amy C. Anderson, Michael P. Pollastri, Celia A. Schiffer, Norton P. Peet · 2011 · Drug Discovery Today
  55. Structural Differences between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors
    Melissa A. Lowder, Amy E. Doerner, Alanna Schepartz · 2015 · Journal of the American Chemical Society
  56. Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase
    Zheng Ruan, Samiksha Katiyar, Natarajan Kannan · 2016 · Biochemistry
  57. Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
    Chen Hu, Aoli Wang, Hong Wu, Ziping Qi, Xixiang Li, Xiao-E Yan, Chen Cheng, Kailin Yu, Fengming Zou, Wenchao Wang et al. · 2017 · Oncotarget
  58. Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors
    Weiwei Han, Yongli Du · 2017 · Chemistry & Biodiversity
  59. Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC
    Lingfeng Chen, Weitao Fu, Chen Feng, Rong Qu, Linjiang Tong, Lulu Zheng, Bo Fang, Yinda Qiu, Jie Hu, Yuepiao Cai et al. · 2017 · European Journal of Medicinal Chemistry
  60. Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
    Nele Van Der Steen, Elisa Giovannetti, Daniela Carbone, Alessandro Leonetti, Christian Diego Rolfo, Godefridus J. Peters · 2018 · Cancer Drug Resistance
  61. Applications of liquid biopsy in lung cancer-diagnosis, prognosis prediction, and disease monitoring.
    Wenna Luo, Mingliang Rao, Jiayao Qu, Dixian Luo · 2018 · Europe PMC (PubMed Central)
  62. Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor
    Naoyuki Nishiya, Yusuke Oku, Chie Ishikawa, Tsutomu Fukuda, Shingo Dan, Tetsuo Mashima, Masaru Ushijima, Yoko Furukawa, Yuka Sasaki, Keishi Otsu et al. · 2021 · Cancer Science
  63. On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein
    Karim M. ElSawy, Chandra Shekhar Verma, David Philip Lane, Leo S. D. Caves · 2013 · Cell Cycle
  64. Epidermal growth factor receptor ( EGFR ) structure‐based bioactive pharmacophore models for identifying next‐generation inhibitors against clinically relevant EGFR mutations
    Pooja S. Panicker, Anu Rohit Melge, Lalitha Biswas, Keechilat Pavithran, C. Gopi Mohan · 2017 · Chemical Biology & Drug Design
  65. Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials
    Le Yu, Ruoyi Yang, Zeng Long, Qingxiu Tao, Bin Liu · 2024 · Frontiers in Oncology
  66. Design, Synthesis, and Biological Evaluation of Novel Diaminopyrimidine Macrocycles as Fourth Generation Reversible EGFR Inhibitors That Overcome Clinical Resistance to Osimertinib Mediated by C797S Mutation
    Shiliang Hu, Linjiang Tong, Qiao Qin, Jiaxin Wen, Yan Li, Feng Fang, Kunzhong Wu, Yang Zhou, Jinsai Shang, Junjian Wang et al. · 2024 · Journal of Medicinal Chemistry
  67. Dual-Targeting TrxR-EGFR Alkynyl-Au(I) Gefitinib Complex Induces Ferroptosis in Gefitinib-Resistant Lung Cancer via Degradation of GPX4
    Lingling Wang, Xiaoyan Ma, Ling De Zhou et al. · 2025 · Journal of Medicinal Chemistry
  68. Mutations of the epidermal growth factor receptor gene in NSCLC patients
    Bing Han, XIANG ZHOU, Rongxin Zhang, Wang‐Fu Zang, ZHONG-YUAN CHEN, Huai‐Dong Song, Huanying Wan, Cuixia Zheng · 2011 · Oncology Letters
  69. Metal‐Containing Pharmacophores in Molecularly Targeted Anticancer Therapies and Diagnostics
    Mu Yang, Ulrich Bierbach · 2016 · European Journal of Inorganic Chemistry
  70. Characterizing Protein–Ligand Binding Using Atomistic Simulation and Machine Learning: Application to Drug Resistance in HIV-1 Protease
    Troy W. Whitfield, Debra A. Ragland, Konstantin B. Zeldovich, Celia A. Schiffer · 2019 · Journal of Chemical Theory and Computation
  71. Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
    Galatea Kallergi, Emmanouil Kontopodis, Aliki Ntzifa, Núria Jordana‐Ariza, Niki Karachaliou, Evangelia Pantazaka, Haris Charalambous, Amanda K. Psyrri, Emily G. Tsaroucha, Ioannis Boukovinas et al. · 2022 · Cancers
  72. Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
    Rui Kitadai, Yusuke Okuma · 2022 · Cancers
  73. EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
    Pei‐Shan Wu, Miao‐Hsia Lin, Jye‐Chian Hsiao, Pei-Yi Lin, Szu‐Hua Pan, Yu‐Ju Chen · 2023 · Molecular & Cellular Proteomics
  74. Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma
    Kian Ngiap Chua, Li Ren Kong, Wen Jing Sim, Hsien Chun Ng, Weijie Richard Ong, Jean Paul Thiery, Hung The Huynh, Boon Cher Goh · 2015 · Oncotarget
  75. Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome
    Jordi Remón, Teresa Morán, Noemı́ Reguart, Margarita Majem, Enric Carcereny, PILAR LIANES · 2014 · Cancer Treatment Reviews
  76. Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors
    Chun Han, Ledong Wan, Hongbin Ji, Ke Ding, Zhangjian Huang, Yisheng Lai, Sixun Peng, Yihua Zhang · 2014 · European Journal of Medicinal Chemistry
  77. Epidermal growth factor receptor inhibitors: a patent review (2010 – present)
    Sining Li, Huan‐Qiu Li · 2014 · Expert Opinion on Therapeutic Patents
  78. SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo
    Youli Pan, Yong Xu, Shan Feng et al. · 2012 · Molecular Cancer Therapeutics
  79. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors
    Ryan P. Wurz, Liping H. Pettus, Kate Ashton, James Brown, Jian Jeffrey Chen, Brad Herberich, Fang‐Tsao Hong, Essa Hu Harrington, Tom T. Nguyen, David J. St. Jean et al. · 2015 · ACS Medicinal Chemistry Letters
  80. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
    Nibal Saad, Aarati Poudel, Alina Basnet, Ajeet Gajra · 2017 · OncoTargets and Therapy
  81. Potential peptidic proteasome inhibitors by incorporation of an electrophilic trap based on amino acid derived α-substituted sulfonyl fluorides
    Natalia Herrero Alvarez, Helmus van de Langemheen, Arwin J. Brouwer, Rob M. J. Liskamp · 2017 · Bioorganic & Medicinal Chemistry
  82. PKPD modeling of acquired resistance to anti-cancer drug treatment
    Miro Julian Eigenmann, Nicolas Frances, Thierry Lavé · 2017 · Journal of Pharmacokinetics and Pharmacodynamics
  83. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition
    Harun Patel, Rahul H. Pawara, Sanjay Javerilal Surana · 2018 · Computational Biology and Chemistry
  84. Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
    Ningning Zhang, Caixia Liang, Wenya Song, Dan Tao, Jiarui Yao, Shuai Wang, Li Ma, Yuankai Shi, Xiaohong Han · 2019 · Journal of Cancer
  85. Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis
    Qinfang Deng, Qiyu Fang, Xianxiu Ji, Songwen Zhou · 2020 · Journal of Cancer
  86. Insights into the structure and drug design of benzimidazole derivatives targeting the epidermal growth factor receptor (EGFR)
    Mar’iyah Najihah Abdullah, Yousaf Ali, Shafida Abd Hamid · 2021 · Chemical Biology & Drug Design
  87. Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells
    Vehary A. Sakanyan, Marie Angelini, Mickael Le Béchec, Michèle Lecocq, Florence Benaiteau, Bénédicte Rousseau, Aram Gyulkhandanyan, Lusine Gyulkhandanyan, Cédric Logé, Éric Reiter et al. · 2014 · Scientific Reports
  88. Nitric oxide donating anilinopyrimidines: Synthesis and biological evaluation as EGFR inhibitors
    Chun Han, Zhangjian Huang, Chao Zheng, Ledong Wan, Yisheng Lai, Sixun Peng, Ke Ding, Hongbin Ji, Yihua Zhang · 2013 · European Journal of Medicinal Chemistry
  89. Leak Proof PDBBind: A Reorganized Dataset of Protein-Ligand Complexes for More Generalizable Binding Affinity Prediction
    Jie Li, Xingyi Guan, Oufan Zhang, Kunyang Sun, Yingze Wang, Dorian Bagni, Teresa L. Head-Gordon · 2023 · PubMed
  90. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update
    Robert Jr. Roskoski · 2025 · Pharmacological Research
  91. Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment
    Isamu Okamoto, Yoshida, Kaneda · 2013 · Cancer Management and Research
  92. Target Therapy in Lung Cancer
    Stefano Cafarotti, Filippo Lococo, Patrizia Frösch, Francesco Zappa, André Dutly · 2015 · Advances in experimental medicine and biology
  93. Combined Quantum Mechanics and Molecular Mechanics Studies of Enzymatic Reaction Mechanisms
    Jon Ainsley, Alessio Lodola, Adrian John Mulholland, Christo Z. Christov, Tatyana G. Karabencheva‐Christova · 2018 · Advances in protein chemistry and structural biology
  94. Genotype-determined EGFR-RTK heterodimerization and its effects on drug resistance in lung Cancer treatment revealed by molecular dynamics simulations
    Mengxu Zhu, Debby D. Wang, Hong Yan · 2021 · BMC Molecular and Cell Biology
  95. A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
    Bart Koopman, Betzabel N. Cajiao Garcia, Chantal C. H. J. Kuijpers, Ronald A.M. Damhuis, Anthonie J. van der Wekken, Harry J.M. Groen, Ed M. D. Schuuring, Stefan M. Willems, Léon C.L.T. van Kempen · 2021 · Cancers
  96. Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer
    Geoffrey R. Oxnard · 2012 · Archives of Pathology & Laboratory Medicine
  97. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells
    Judith Niesen, Hannes Brehm, Christoph Stein · 2014 · Journal of Cancer Research and Clinical Oncology
  98. EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib
    Juliann Chmielecki, Maria Catherine Pietanza, Dana T. Aftab, Ronglai Shen, Zhiguo Zhao, Xi Chen, Katherine E. Hutchinson, Agnes J. Viale, Mark G. Kris, Thomas J. Stout et al. · 2011 · Journal of Thoracic Oncology
  99. Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Jair Bar, Amir Onn · 2011 · Clinical Lung Cancer
  100. Dynamic Protein Allosteric Regulation and Disease
    Nussinov, Ruth, Tsai, Chung-Jung, Jang, Hyunbum · 2019 · Advances in Experimental Medicine and Biology